- Oral presentation
- Open Access
Serious infections in JIA patients upon MTX, TFN inhibitors and combinations
© Horneff and Becker; licensee BioMed Central Ltd. 2014
- Published: 17 September 2014
- Biker Registry
- Potential Risk Factor
Serious infections are a major concern in JIA patients treated with immunosuppressants and biologics. Effect of TNF inhibitors on the risk for serious infections and further factors are studied here.
Pts exposed to Etanercept (ETA), Adalimumab (ADA) and Methotrexate (MTX) but no biologics and serious infections were identified in the BIKER registry. Descriptive statistics, infection rates, Cox-regression, Hazard ratios (HR) were calculated. Potential risk factors were analysed.
ADA / MTX
ETA / MTX
More than 1 DMARD failure
Pretreatment with steroids
Steroids at baseline
ETA and ADA treatment as well as higher disease activity contribute to serious infections.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.